Evoke Pharma (EVOK) Competitors $2.86 -0.10 (-3.22%) As of 02:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVOK vs. SXTC, OVID, NAII, SLGL, BIVI, CGTX, CMMB, ASBP, LGVN, and ELEVShould you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include China SXT Pharmaceuticals (SXTC), Ovid Therapeutics (OVID), Natural Alternatives International (NAII), Sol-Gel Technologies (SLGL), BioVie (BIVI), Cognition Therapeutics (CGTX), Chemomab Therapeutics (CMMB), Aspire Biopharma (ASBP), Longeveron (LGVN), and Elevation Oncology (ELEV). These companies are all part of the "pharmaceutical products" industry. Evoke Pharma vs. Its Competitors China SXT Pharmaceuticals Ovid Therapeutics Natural Alternatives International Sol-Gel Technologies BioVie Cognition Therapeutics Chemomab Therapeutics Aspire Biopharma Longeveron Elevation Oncology Evoke Pharma (NASDAQ:EVOK) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations. Does the MarketBeat Community favor EVOK or SXTC? Evoke Pharma received 278 more outperform votes than China SXT Pharmaceuticals when rated by MarketBeat users. However, 61.65% of users gave China SXT Pharmaceuticals an outperform vote while only 57.69% of users gave Evoke Pharma an outperform vote. CompanyUnderperformOutperformEvoke PharmaOutperform Votes36057.69% Underperform Votes26442.31% China SXT PharmaceuticalsOutperform Votes8261.65% Underperform Votes5138.35% Does the media prefer EVOK or SXTC? In the previous week, Evoke Pharma and Evoke Pharma both had 2 articles in the media. Evoke Pharma's average media sentiment score of 0.94 beat China SXT Pharmaceuticals' score of 0.43 indicating that Evoke Pharma is being referred to more favorably in the media. Company Overall Sentiment Evoke Pharma Positive China SXT Pharmaceuticals Neutral Do institutionals and insiders believe in EVOK or SXTC? 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 2.3% of Evoke Pharma shares are held by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is EVOK or SXTC more profitable? China SXT Pharmaceuticals has a net margin of 0.00% compared to Evoke Pharma's net margin of -71.32%. China SXT Pharmaceuticals' return on equity of 0.00% beat Evoke Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Evoke Pharma-71.32% -308.49% -53.66% China SXT Pharmaceuticals N/A N/A N/A Which has more volatility and risk, EVOK or SXTC? Evoke Pharma has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Which has better valuation and earnings, EVOK or SXTC? China SXT Pharmaceuticals has lower revenue, but higher earnings than Evoke Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvoke Pharma$11.59M0.37-$7.79M-$2.87-0.99China SXT Pharmaceuticals$1.82M16.10-$3.10MN/AN/A SummaryChina SXT Pharmaceuticals beats Evoke Pharma on 9 of the 12 factors compared between the two stocks. Get Evoke Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVOK vs. The Competition Export to ExcelMetricEvoke PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.26M$6.88B$5.59B$8.51BDividend YieldN/A2.53%5.28%4.17%P/E Ratio-0.268.5427.2019.68Price / Sales0.37262.76409.08153.66Price / CashN/A65.8538.3234.64Price / Book-0.316.526.974.61Net Income-$7.79M$143.48M$3.23B$248.06M7 Day Performance-3.22%0.36%-0.72%-0.82%1 Month Performance-9.08%11.11%8.00%3.74%1 Year Performance-54.69%2.62%31.77%13.02% Evoke Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOKEvoke Pharma0.6161 of 5 stars$2.86-3.2%N/A-54.9%$4.26M$11.59M-0.264Gap UpSXTCChina SXT Pharmaceuticals0.3784 of 5 stars$1.32-5.0%N/A-77.4%$20.89M$1.82M0.0090Short Interest ↑Gap DownOVIDOvid Therapeutics4.3922 of 5 stars$0.29+6.5%$2.78+860.1%-91.0%$20.62M$548K-0.6260NAIINatural Alternatives International0.7706 of 5 stars$3.31-0.4%N/A-47.7%$20.43M$125.48M-2.56290News CoveragePositive NewsShort Interest ↑SLGLSol-Gel Technologies3.0315 of 5 stars$7.32+1.5%$40.00+446.7%-11.5%$20.38M$12.10M-21.5250Positive NewsShort Interest ↓BIVIBioVie2.4521 of 5 stars$1.07+2.9%$3.00+180.4%+142.1%$19.86MN/A-0.1110CGTXCognition Therapeutics3.6809 of 5 stars$0.32+32.6%$5.63+1,674.4%-87.1%$19.65MN/A-0.3320Short Interest ↓Gap UpHigh Trading VolumeCMMBChemomab Therapeutics3.6083 of 5 stars$1.35+2.3%$8.50+529.6%+11.4%$19.39MN/A-1.3520Positive NewsASBPAspire BiopharmaN/A$0.39-10.5%N/AN/A$19.07MN/A0.00N/ANews CoverageGap DownLGVNLongeveron3.5307 of 5 stars$1.25+0.8%$8.67+593.3%-27.1%$18.66M$2.23M-0.2020Gap DownELEVElevation Oncology3.3897 of 5 stars$0.31+3.7%$3.39+987.6%-88.7%$18.44MN/A-0.3840Trending NewsAnalyst ForecastShort Interest ↓Analyst Revision Related Companies and Tools Related Companies SXTC Alternatives OVID Alternatives NAII Alternatives SLGL Alternatives BIVI Alternatives CGTX Alternatives CMMB Alternatives ASBP Alternatives LGVN Alternatives ELEV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVOK) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
